REVAMP: Management Guided by Genotypic Resistance Testing Following First-line ART Failure Comparable to Viral Load–Guided Management in Sub-Saharan Africa

March 6-10, 2021; Virtual
Study finds that use of genotypic resistance testing to guide management of patients experiencing first-line ART failure does not improve viral suppression rates, highlighting need for alternative strategies to improve management of ART failure.
Format: Microsoft PowerPoint (.ppt)
File Size: 183 KB
Released: March 8, 2021


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from CCO: Switching ART in HIV: 3-drug therapy, oral 2-drug options, long-acting injectable 2-drug regimens, single tablet regimens (STRs)

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

Slides from Daniel Kuritzkes and CCO. Switching to long-acting cabotegravir: ATLAS and FLAIR data, starting, dosing regimens, avoiding treatment failure

Daniel R. Kuritzkes, MD Released: June 4, 2021

Drs Roger Bedimo, Princy N. Kumar, and Brian Wood, answer commonly asked questions on managing heavily treatment-experienced patients with HIV

Roger Bedimo, MD, MS, FACP Princy N. Kumar, MD, FIDSA, MACP Brian Wood, MD Released: June 2, 2021

Download free CCO slides reviewing a patient case and key data and guidelines on weight gain in aging persons with HIV

Karine Lacombe, MD, PhD Released: May 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.